S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
NYSE:IQV

IQVIA (IQV) Stock Price, News & Analysis

$252.95
+0.38 (+0.15%)
(As of 03:58 PM ET)
Today's Range
$247.96
$253.77
50-Day Range
$208.23
$259.15
52-Week Range
$167.42
$261.73
Volume
458,525 shs
Average Volume
1.02 million shs
Market Capitalization
$45.91 billion
P/E Ratio
34.70
Dividend Yield
N/A
Price Target
$256.80

IQVIA MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
1.7% Upside
$256.80 Price Target
Short Interest
Healthy
1.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.61mentions of IQVIA in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$10.33 M Sold Last Quarter
Proj. Earnings Growth
13.95%
From $10.11 to $11.52 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

138th out of 939 stocks

Commercial Physical Research Industry

4th out of 10 stocks

IQV stock logo

About IQVIA Stock (NYSE:IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

IQV Stock Price History

IQV Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NVO Mar 2024 90.000 put
IQV Dec 2024 210.000 put
6 Best Biotech Stocks to Buy for 2024
The obese numbers
Q4 2023 ANI Pharmaceuticals Inc Earnings Call
IQVIA Holdings Inc.: Raising target to $300 from $260
See More Headlines
Receive IQV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Fax
N/A
Employees
87,000
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$256.80
High Stock Price Target
$300.00
Low Stock Price Target
$220.00
Potential Upside/Downside
+1.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$1.36 billion
Pretax Margin
9.74%

Debt

Sales & Book Value

Annual Sales
$14.98 billion
Cash Flow
$16.04 per share
Book Value
$33.49 per share

Miscellaneous

Free Float
178,596,000
Market Cap
$45.81 billion
Optionable
Optionable
Beta
1.51

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of IQVIA was last updated on Monday, March 25, 2024 at 11:32 PM.

Pros

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry globally, offering a diversified portfolio of services that cater to a wide range of needs within the industry.
  • The company operates through three segments, including Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, providing investors with exposure to multiple facets of the life sciences sector.
  • IQVIA Holdings Inc. collaborates with various companies and has a strong presence in different regions, which can potentially lead to increased market share and revenue growth.
  • With an expected EPS of 10.05 for the current year, the company demonstrates strong earnings potential, which could attract investors looking for profitable opportunities.
  • The company's focus on advanced analytics and technology solutions positions it well to capitalize on the increasing demand for data-driven insights and digital transformation in the healthcare industry.

Cons

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • While the company offers a wide range of services, the competitive landscape in the life sciences industry is intense, which could potentially impact IQVIA's market position and profitability.
  • Fluctuations in the healthcare sector, regulatory changes, or unexpected events like pandemics can significantly influence the company's performance and stock price, leading to investment risks.
  • Investing in commercial physical research companies like IQVIA Holdings Inc. requires a good understanding of the industry dynamics, regulatory environment, and technological advancements, which may pose challenges for some investors.
  • Market volatility and economic uncertainties can affect the company's financial performance and stock valuation, making it a potentially risky investment during uncertain times.
  • Investors should carefully assess the company's financial health, growth prospects, and competitive positioning before making investment decisions to mitigate risks associated with investing in IQVIA Holdings Inc.

IQV Stock Analysis - Frequently Asked Questions

Should I buy or sell IQVIA stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IQV shares.
View IQV analyst ratings
or view top-rated stocks.

What is IQVIA's stock price target for 2024?

15 Wall Street analysts have issued 1 year price objectives for IQVIA's shares. Their IQV share price targets range from $220.00 to $300.00. On average, they expect the company's stock price to reach $256.80 in the next year. This suggests a possible upside of 1.7% from the stock's current price.
View analysts price targets for IQV
or view top-rated stocks among Wall Street analysts.

How have IQV shares performed in 2024?

IQVIA's stock was trading at $231.38 on January 1st, 2024. Since then, IQV stock has increased by 9.1% and is now trading at $252.41.
View the best growth stocks for 2024 here
.

Are investors shorting IQVIA?

IQVIA saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,200,000 shares, an increase of 9.2% from the February 29th total of 2,930,000 shares. Based on an average daily trading volume, of 993,600 shares, the short-interest ratio is currently 3.2 days. Approximately 1.8% of the company's shares are sold short.
View IQVIA's Short Interest
.

When is IQVIA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our IQV earnings forecast
.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) announced its quarterly earnings results on Wednesday, February, 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.82 by $0.02. The medical research company earned $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a trailing twelve-month return on equity of 29.32% and a net margin of 9.06%. IQVIA's revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.54 earnings per share.
Read the conference call transcript
.

What guidance has IQVIA issued on next quarter's earnings?

IQVIA updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of 10.950-11.250 for the period, compared to the consensus EPS estimate of 11.060. The company issued revenue guidance of $15.4 billion-$15.7 billion, compared to the consensus revenue estimate of $15.6 billion.

What is Ari Bousbib's approval rating as IQVIA's CEO?

1,545 employees have rated IQVIA Chief Executive Officer Ari Bousbib on Glassdoor.com. Ari Bousbib has an approval rating of 84% among the company's employees.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IQVIA investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), PayPal (PYPL), Salesforce (CRM) and Accenture (ACN).

Who are IQVIA's major shareholders?

IQVIA's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.61%), Mitsubishi UFJ Asset Management Co. Ltd. (1.33%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (1.13%), Capital Research Global Investors (1.09%), Cantillon Capital Management LLC (0.99%) and Wellington Management Group LLP (0.95%). Insiders that own company stock include Ari Bousbib, Constantinos Panagos, Eric Sherbet, John Connaughton, John G Danhakl and Kevin C Knightly.
View institutional ownership trends
.

How do I buy shares of IQVIA?

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does IQVIA have any subsidiaries?
The following companies are subsidiares of IQVIA: 159 Solutions LLC, 159 Technology Solutions Private Ltd, AECIO IT Solutions India Private Ltd., ALIMED Egeszsegugyi Szolgaltato Kft., Advanced Health Media LLC, Advanced Health Media Services Ltd., Aileron Solutions, Albatross Financial Solutions Limited, Allcare Plus Pharmacy LLC, Aposphäre GmbH, Appature Inc., Ardentia International Limited, Ascott Sales Integration Pty Ltd, Asesorias IQVIA Solutions Chile Limitada, Asserta Centroamerica Medicion de Mercados S.A., Avacare Clinical Research Network (Shanghai) Co. Ltd., BUZZEOPDMA LLC, Battaerd Mansley (Proprietary) Limited, Battaerd Mansley Pty. Ltd., Benefit Holding Inc., Biofortis LLC, Branch of IQVIA RDS GesmbH in Novosibirsk, Branch of IQVIA RDS GesmbH in St. Petersburg, CDS - Centre de Service SAS, CFS Clinical UK Limited, CRM Health Korea Ltd., CSD Health Korea Ltd., CT Clinical Portugal Unipessoal Lda, CT Clinical Services Eood, CT Consulting Inc., Cambridge Pharma Consultancy Inc., Cambridge Pharma Consultancy Limited, Cegedim Venezuela C.A., Cenduit (India) Services Private Company Limited, Cenduit GmbH, Cenduit Holdings LLC, Cenduit LLC, Cenduit LLC Shanghai Rep. Office, Cenduit Limited, Cenduit Mauritius Holdings Company, Centrix Innovations (Pty) Ltd., ClinTec Austria GmbH, ClinTec CRO Services (India) Private Limited, ClinTec Gesellschaft fur Klinische Entwicklung GmbH, ClinTec International (Pty) Ltd., ClinTec International (Pty) Ltd. (Malawi branch), ClinTec International (Thailand) Limited, ClinTec International AG, ClinTec International Belgium BV, ClinTec International Bulgaria OOD, ClinTec International Co. Ltd., ClinTec International Denmark ApS, ClinTec International FZ-LLC, ClinTec International Hong Kong Limited, ClinTec International Hungary Kft, ClinTec International Italy S.r.l., ClinTec International LLC, ClinTec International Limited, ClinTec International Ltd (Netherlands Branch), ClinTec International Ltd UK Filial Sverige, ClinTec International Ltd., ClinTec International Norway AS, ClinTec International Off-Shore S.A.L., ClinTec International Pte Ltd., ClinTec International Pty Ltd, ClinTec International RUS LLC, ClinTec International Romania S.R.L., ClinTec International S.à r.l., ClinTec International SL, ClinTec International Services Inc., ClinTec International d.o.o. za trgov inuisludge, ClinTec International doo, ClinTec International s.r.o., ClinTec International sp. z.o.o., ClinTec Luxembourg S.A., ClinTec Turkey Medikal ve Farmasotik Hizmetler Ticaret Limited Sirketi, ClinTech Ireland International Research Limited, Clinical Financial Services LLC, Clinical Insourcing Solutions Limited, Clinical Insourcing Solutions S. de R.L. de C.V., Clinical Lab Minority Shareholder Limited, Clintec International Inc., Clintec International Pharmaceutical Services Ltd, Compliant Community Projects (Pty) Ltd., CoreZetta Co Ltd., Data Niche Associates Inc., Dataline Software Limited, Datandina Ecuador S.A., Datec Industria e Comercio Distribudora Grafica e Mala Direta Ltda., Dimensions Healthcare Company Ltd, Dimensions Healthcare LLC, Dimensions Healthcare LLC (Dubai Branch), DrugDev, DrugDev Inc., DrugDev Limited, EA Institute L.L.C., EPID Research Oy, EPID Research Sweden, EPS Research Limited, EPS Software Limited, Enterprise Associates L.L.C., Epernicus LLC, Excel Life Sciences Inc., Excel Life Sciences Pvt Ltd India, Forcea NV, Foresight IT Solutions and Consulting India Private Limited, GCE Clin Solutions Limited, GCE Global Solutions LLC, GCE Solutions GmbH, GCE Solutions International LLC, GCE Solutions Proprietary Limited, GCE Solutions S. de R.L. de C.V., Global Crown Investment Limited, Grace Data Corp., HighPoint Solutions LLC, Highpoint Solutions LLC (Geneva Branch), Hospital Marketing Services Ltd., Hotel Lot C-8B LLC, IMS (UK) Pension Plan Trustee Company Limited, IMS AB, IMS Government Solutions Inc., IMS HEALTH GROUP LIMITED, IMS HEALTH KOREA LTD., IMS Health (Australia) Partnership, IMS Health Analytics Services Private Limited, IMS Health Information Solutions Australia Pty. Ltd, IMS Health Information Solutions India Private Ltd., IMS Health Networks Limited, IMS Health Paraguay SRL, IMS Health Surveys Limited, IMS Health Uruguay S.A., IMS Health de Venezuela C.A., IMS Hospital Group Limited, IMS Information Solutions Medical Research Limited, IMS Information Solutions UK Ltd., IMS International (Proprietary) Limited, IMS Meridian Limited, IMS Meridian Research Limited, IMS SOFTWARE SERVICES LTD., IMS Technology Solutions UK Limited, INCARNUS MALAYSIA SDN BHD, IPP Informacion Promocional y Publicitaria S.A. de C.V., IQVIA (Thailand) Co. Ltd., IQVIA AB, IQVIA AG, IQVIA AG (Basal Branch), IQVIA AG (Dubai Branch), IQVIA AG (Mexico Branch), IQVIA AG (Representative Office - Algeria), IQVIA AG (Representative Office - Dubai), IQVIA AG (Representative Office - Jordan), IQVIA AG (Representative Office - Lebanon), IQVIA AG (Representative Office - Serbia), IQVIA AG (Rotkreuz Branch), IQVIA AG (UK Branch), IQVIA Adriatic d.o.o. za Konzalting, IQVIA Asia Pacific Commercial Holdings LLC, IQVIA Beteiligungsgesellschaft mbH, IQVIA BioSciences Holdings LLC, IQVIA Biotech LLC, IQVIA Biotech Ltd., IQVIA CHINAMETRIK INC., IQVIA COMMERCIAL FINANCE INC., IQVIA COMMERCIAL INDIA HOLDINGS CORP., IQVIA COMMERCIAL SERVICES LLC, IQVIA COMMERCIAL TRADING CORP., IQVIA CSMS GmbH, IQVIA CSMS US Inc., IQVIA Clinical AB, IQVIA Clinical Filial af IQVIA Clinical AB, IQVIA Commercial Consulting Sp. z.o.o., IQVIA Commercial Deutschland GmbH, IQVIA Commercial GmbH & Co. OHG, IQVIA Commercial I LLC, IQVIA Commercial Software GmbH, IQVIA Commercial Sp. z.o.o., IQVIA Consulting Solutions BV, IQVIA Consulting and Information Services India Private Limited, IQVIA FZ-LLC, IQVIA Finance Ireland Designated Activity Company, IQVIA GOVERNMENT SOLUTIONS INC., IQVIA Healthcare (QFC Branch), IQVIA Hellas Technology Solutions Single Member S.A., IQVIA Holdings (UK) Ltd., IQVIA Holdings France SAS, IQVIA IES Brasil Ltda., IQVIA IES Denmark ApS, IQVIA IES Europe Limited, IQVIA IES European Holdings, IQVIA IES Italia S.r.l., IQVIA IES OY, IQVIA IES Overseas Holdings Limited, IQVIA IES Portugal Unipessoal LDA, IQVIA IES Puerto Rico Inc., IQVIA IES South Africa (Pty) Limited, IQVIA IES UK Limited, IQVIA II Technology Solutions Portugal Unipessoal LDA, IQVIA INC., IQVIA INFORMATION MEDICAL STATISTICS (ISRAEL) LTD., IQVIA Inc. (Thailand Branch), IQVIA Information S.A., IQVIA Information Solutions (China) Co. Ltd., IQVIA Information Solutions GmbH, IQVIA Integrated Services NL, IQVIA Investment Holdings Limited, IQVIA Korea Co. Ltd., IQVIA LTD., IQVIA Lebanon S.a.r.l., IQVIA Market Intelligence LLC, IQVIA Marktforschung GmbH, IQVIA Maroc S.à r.l., IQVIA MedTech Inc., IQVIA MedTech NV, IQVIA Medical Communications & Consulting Inc., IQVIA Medical Development (Dalian) Co. Ltd., IQVIA Medical Education Inc., IQVIA Medical Radar AB, IQVIA Operations France SAS, IQVIA PHARMA Inc., IQVIA Partners AS, IQVIA Pharma Services Corp., IQVIA Pharmaceutical Marketing Services Ltd., IQVIA Phase One Services LLC, IQVIA RDS (India) Private Ltd., IQVIA RDS (Pty.) Limited, IQVIA RDS (Shanghai) Co. Ltd., IQVIA RDS AG, IQVIA RDS Argentina S.R.L., IQVIA RDS Asia Inc., IQVIA RDS Austria GmbH, IQVIA RDS BT Inc., IQVIA RDS Brasil Ltda., IQVIA RDS Bulgaria EOOD, IQVIA RDS Canada ULC, IQVIA RDS Chile, IQVIA RDS Clindata (Pty.) Ltd., IQVIA RDS Clindepharm (Pty.) Ltd., IQVIA RDS Colombia S.A.S., IQVIA RDS Costa Rica S.A., IQVIA RDS Czech Republic s.r.o., IQVIA RDS ESTONIA OU, IQVIA RDS East Asia Pte. Ltd., IQVIA RDS Eastern Holdings GmbH, IQVIA RDS Egypt LLC, IQVIA RDS Finland OY, IQVIA RDS France SAS, IQVIA RDS Funding LLC, IQVIA RDS GesmbH, IQVIA RDS GmbH, IQVIA RDS Guatemala S.A., IQVIA RDS Hellas Single Member S.A., IQVIA RDS Holdings, IQVIA RDS Hong Kong Limited, IQVIA RDS Hungary Pharmaceutical Development and Consulting Limited Liability Company, IQVIA RDS ISRAEL LTD., IQVIA RDS Inc., IQVIA RDS Ireland (Finance) Ltd., IQVIA RDS Ireland Ltd., IQVIA RDS Italy S.r.l., IQVIA RDS Latin America LLC, IQVIA RDS Latin America LLC (Argentina Branch), IQVIA RDS Latvia SIA, IQVIA RDS Malaysia Sdn. Bhd., IQVIA RDS Netherlands B.V., IQVIA RDS Norway, IQVIA RDS Panama Inc., IQVIA RDS Peru S.r.l., IQVIA RDS Philippines Inc., IQVIA RDS Poland Sp. Zoo, IQVIA RDS Pty. Limited, IQVIA RDS Pty. Ltd., IQVIA RDS Slovakia s.r.o., IQVIA RDS South Africa (Pty.) Ltd., IQVIA RDS Spain S.L., IQVIA RDS Spain S.L. - Representação Permanente em Portugal, IQVIA RDS Switzerland S.à r.l., IQVIA RDS Taiwan Ltd., IQVIA RDS UAB, IQVIA RDS UK Holdings Ltd., IQVIA RDS Ukraine, IQVIA RDS Vietnam LLC, IQVIA RDS and Integrated Services Belgium NV, IQVIA RDS d.o.o. Beograd, IQVIA Research and Development Solutions Saudi Arabia Limited, IQVIA Romania S.R.L., IQVIA SOLUTIONS CANADA INC, IQVIA SOLUTIONS JAPAN K.K., IQVIA Services Japan K.K., IQVIA Solutions (NZ) Limited, IQVIA Solutions (Pty.) Ltd., IQVIA Solutions Argentina S.A., IQVIA Solutions Asia Pte. Ltd, IQVIA Solutions Australia Holdings Pty. Ltd., IQVIA Solutions Australia Pty. Ltd., IQVIA Solutions B.V., IQVIA Solutions Bangladesh Limited, IQVIA Solutions Belgium BV, IQVIA Solutions Bolivia S.R.L., IQVIA Solutions Bulgaria EOOD, IQVIA Solutions Colombia S.A., IQVIA Solutions Consulting Myanmar Company Limited, IQVIA Solutions Denmark AS, IQVIA Solutions Egypt Ltd., IQVIA Solutions Enterprise Management Consulting (Shanghai) Co. Ltd (Beijing Branch), IQVIA Solutions Enterprise Management Consulting (Shanghai) Co. Ltd., IQVIA Solutions Finance B.V., IQVIA Solutions Finance UK I Ltd., IQVIA Solutions Finance UK II Ltd., IQVIA Solutions Finance UK III Ltd., IQVIA Solutions Finance UK V Ltd., IQVIA Solutions Finland OY, IQVIA Solutions Global Holdings UK Ltd., IQVIA Solutions HQ Ltd., IQVIA Solutions Holdings (Pty.) Ltd., IQVIA Solutions Hong Kong Limited, IQVIA Solutions Ireland Limited, IQVIA Solutions Italy S.r.l., IQVIA Solutions Kazakhstan LLC, IQVIA Solutions LLC, IQVIA Solutions Lanka (Private) Limited, IQVIA Solutions Malaysia Sdn. Bhd., IQVIA Solutions Norway AS, IQVIA Solutions Operations Center Philippines Inc., IQVIA Solutions Pakistan (Private) Limited, IQVIA Solutions Pharmaceutical SRL, IQVIA Solutions Philippines Inc., IQVIA Solutions Portugal Lda, IQVIA Solutions Puerto Rico Inc., IQVIA Solutions Regional Pte. Ltd., IQVIA Solutions Republica Dominicana S.R.L., IQVIA Solutions Saudi Arabia Limited, IQVIA Solutions Services Ltd., IQVIA Solutions Sweden AB, IQVIA Solutions Tunisia S.à r.l., IQVIA Solutions UK Investments Ltd., IQVIA Solutions UK Limited, IQVIA Solutions a.s., IQVIA Solutions del Peru S.A., IQVIA Solutions do Brasil Ltda., IQVIA Solutions s.r.o., IQVIA Soluções de Tecnologia do Brasil Ltda, IQVIA Staff Services Sp.A., IQVIA TRANSPORTATION SERVICES CORP., IQVIA Technology Services Ltd., IQVIA Technology Solutions (China) Co. Ltd., IQVIA Technology Solutions Colombia Ltda., IQVIA Technology Solutions Egypt LLC, IQVIA Technology Solutions Finland OY, IQVIA Technology Solutions Poland SP. z.o.o, IQVIA Technology Solutions Romania Srl, IQVIA Technology Solutions S.R.O. (Bulgaria Branch), IQVIA Technology Solutions Ukraine LLC, IQVIA Technology Solutions s.r.o., IQVIA Technology Tunisia S.à r.l., IQVIA Tibbi Istatistik Ticaret ve Musavirlik Ltd. Sirketi, IQVIA Trading Management Inc., IQVIA World Publications Ltd., IQVIA Zagreb d.o.o., Iasist Holdco Limited, Iasist Portugal Consultadoria na Área de Saúde Unipessoal Lda, Iasist SAU Agencia en Chile, Iasist Sociedad Anonima Unipersonal, Impact RX Data Management (Pty) Ltd., Infocus Health Limited, Infopharm Ltd., Innovex Holdings I LLC, Innovex Merger Corp., Innovex Saglik Urunleri Pazarlame ve Hizmet Danismanlik Anonim Sirketi, Intercontinental Medical Statistics International Ltd., Intercontinental Medical Statistics Kenya Ltd., Interface Clinical Services Ltd., Interstatistik AG, Iqvia Solutions Taiwan Ltd., Jäger Health Gmbh, Kun Tai Medical Development Hong Kong Limited, Kun Tuo Medical Research & Development (Beijing) Co. Ltd., Laboratorio Commuq Pharma SLU, Linguamatics, Linguamatics Limited, Linguamatics Solutions Limited, M&H Informatics (BD) LTD., Mecurial Insights Holding Pty. Ltd., Mecurial Insights Pty. Ltd., Med-Vantage Inc., Meddata Group LLC, MedicSense Ltd., Medineos S.r.l., Mercados Y Analisis S.A., Meridian Research Vietnam Ltd., Novasyte LLC, Novella Clinical LLC, Novex Pharma Laboratorio S.L., Novex Pharma Limited, Nuevo Health Pty Ltd, Operaciones Centralizadas Latinoamericana Limitada, Optimum Contact Limited, Outcome Sciences LLC, PR Editions S.A.S., PT IQVIA RDS Indonesia, PT IQVIA Solutions Indonesia, Penderwood Limited, PharmARC Consulting Services GmbH, PharmARC Inc., Pharma Deals Limited, Pharma Strategy Group Limited, Pharmadata s.r.o., Pharmaforce S.A. de C.V., Polaris Management Partners LLC, Polaris Solutions LLC, Polaris Solutions Ltd., Privacy Analytics Inc., Professional Pharmaceutical Marketing Services (Pty.) Ltd., Prometheus Research LLC, Public Relations Algeria, Q Squared Solutions (Beijing) Co. Ltd., Q Squared Solutions (India) Private Limited, Q Squared Solutions (Quest) LLC, Q Squared Solutions (Quest) Limited, Q Squared Solutions (Shanghai) Co. Ltd., Q Squared Solutions B.V., Q Squared Solutions BioSciences LLC, Q Squared Solutions China (Quest) Limited, Q Squared Solutions China Limited, Q Squared Solutions Expression Analysis LLC, Q Squared Solutions Holdings B.V., Q Squared Solutions Holdings LLC, Q Squared Solutions Holdings Limited, Q Squared Solutions KK, Q Squared Solutions LLC, Q Squared Solutions Limited, Q Squared Solutions Proprietary Limited, Q Squared Solutions Pte. Ltd., Q Squared Solutions S.A., Q2 Solutions, QH Research Limited, QIMS Pharma Services SA DE CV, Qcare Site Services Inc., Quality Health Limited, Quintiles Benin Ltd., Quintiles Clinical and Commercial Nigeria Limited, Quintiles Commercial Laboratorio S.L.U., Quintiles Commercial Rus LLC, Quintiles East Africa Limited, Quintiles Finance Uruguay S.r.L., Quintiles IMS Japan GK, Quintiles Lanka (Private) Limited, Quintiles Mauritius Holdings, Quintiles Medical Development (Shanghai) Co. Ltd., Quintiles Mexico S. de R.L. de C.V., Quintiles New Zealand, Quintiles Phase One Clinical Trials India Private Limited, Quintiles RDS Latin America LLC, Quintiles Site Services S.A., Quintiles West Africa Limited, RX India LLC, Radar Acquisition Blocker Inc., Redsite Limited, Representative Office of IQVIA RDS GesmbH in Moscow, STI Technologies Limited, Schwarzeck Verlag GmbH, Secureconsent LLC, Shanghai IMS Market Research Co. Ltd., Smart I.T. Systems BV, Source Informatics Limited, Spartan Leasing Corporation, StatFin Estonia, Statfinn Oy, Targeted Molecular Diagnostics LLC, Tarius A/S, Temas Srl - Società Unipersonale, TforG Support NV, The Amundsen Group Inc., Themis Limited, UAB IQVIA Commercial, VCG&A Inc., VCG-BIO Inc., Valuecentric Global Services Gmbh, Valuecentric Privacy Solutions LLC, Valuemedics Research LLC, Vivacity Health Pty. Ltd., genae Germany Gmbh, genae International Ag, and iGuard Inc..
Read More
This page (NYSE:IQV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners